Chronic Heart Failure

EFfect of Ferric Carboxymaltose on exercIse CApacity and Cardiac Function in Patients With Iron deficiencY and Chronic Heart Failure

NCT00821717 | PHASE 3 | INTERVENTIONAL

This study is designed to assess, relative to placebo, the effects on the evolution of exercise capacity and symptomatic status of the addition of iron treatment with FCM (ferric carboxymaltose) to the basic regimen of ambulatory patients with stable symptomatic chronic CHF (congestive heart failure) and iron deficiency.

41 Sites

35 Participants

Recruiting

18 Years to 75 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Research Site

Copenhagen S,Denmark

Research Site

Esbjerg,Denmark

Research Site

Fredericia,Denmark

Research Site

Glostrup,Denmark

Research Site

Hellerup,Denmark

Research Site

Herning,Denmark

Research Site

Hilleroed,Denmark

Research Site

Svendborg,Denmark

Research Site

Boulogne,France

Research Site

Dijon,France

Research Site

Lyon,France

Research Site

Montpellier,France

Research Site

Nantes,France

Research Site

Pontoise,France

Research Site

Rennes,France

Research Site

Saintes,France

Research Site

Strasbourg,France

Research Site

Dueren,Germany

Research Site

Frankfurt,Germany

Research Site

Homburg/Saar,Germany

Research Site

Koeln,Germany

Research Site

Mainz,Germany

Research Site

Würzburg,Germany

Research Site

Afula,Israel

Research Site

Ashkelon,Israel

Research Site

Haifa,Israel

Research Site

Holon,Israel

Research Site

Jerusalem,Israel

Research Site

Kfar-Saba,Israel

Research Site

Rehovot,Israel

Research Site

Tel-Aviv,Israel

Research Site

Tel-Hashomer,Israel

Research Site

Zefat,Israel

Research Site

Amsterdam,Netherlands

Research Site

Den Bosch,Netherlands

Research Site

Eindhoven,Netherlands

Research Site

Heerenveen,Netherlands

Research Site

Leiden,Netherlands

Research Site

Nieuwegein,Netherlands

Research Site

Tilburg,Netherlands

Research Site

Utrecht,Netherlands

Study Eligibility Criteria

Inclusion Criteria

* In New York Heart Association (NYHA) II-III functional class due to stable symptomatic chronic heart failure (CHF)
* Left ventricular ejection fraction (LVEF) 40% or lower for patients in NYHA II and 45% or lower in NYHA III
* Screening haemoglobin (Hb) at least 9.5 g/dL but below or equal to 13.5 g/dL (average of 2 haemoglobin concentrations)
* Screening ferritin below 100 µg/L, or below 300 µg/L when transferrin saturation (TSAT) is below 20%

Exclusion Criteria

* History of acquired iron overload.
* Known active infection, clinically significant bleeding, active malignancy.
* Chronic liver disease and/or screening alanine transaminase (ALT) or aspartate transaminase (AST)
* Anaemia due to reasons other than iron deficiency
* Immunosuppressive therapy or renal dialysis (current or planned within the next 6 months).
* History of erythropoietin, i.v. or oral iron therapy, and blood transfusion in previous 12 weeks and/or such therapy planned within the next 6 months.
* Unstable angina pectoris as judged by the investigator, clinically significant uncorrected valvular disease or left ventricular outflow obstruction, obstructive cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly controlled symptomatic brady- or tachyarrhythmias.
* Acute myocardial infarction or acute coronary syndrome, transient ischaemic attack or stroke within the last 3 months.
* Coronary-artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including thoracic and cardiac surgery, within the last 3 months.

Additional Studies

Additional studies can be found at ClinicalTrials.gov